Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter
Professionals >> Visit The Body PROThe Body en Espanol
Home Page for TheBody.com, the Complete HIV/AIDS Resource What's New About HIV Ask the Experts About HIV HIV/AIDS Blogs Connect With Others About HIV Just Diagnosed With HIV HIV Treatment HIV Prevention Living With HIV Personal Stories of People With HIV
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

HIV Pipeline: Chart on Drugs in Development

Source: Ben Cheng, Project Inform4
 From The Center for AIDS

Summer 2002

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Compound Class of Compound Phase of Development Pharmaceutical Company
ACH-126,443 (L-Fd4C) nucleoside analog RT inhibitor Phase 1 Achilleon
ADA zinc finger Phase 1-2 Hubriphar
AMD-34653 CXCR4 antagonist Preclinical AnorMed
AMD-84453 entry inhibitor Preclinical AnorMed
Atazanavir (BMS-232623) protease inhibitor Phase 2-31 Bristol-Myers Squibb
BCH-10618 (DOTC) nucleoside analog RT inhibitor Preclinical Shire Biochem
BEA-0053 nucleoside analog RT inhibitor Preclinical Medivir
Beta-D-Fd4C3 nucleoside analog RT inhibitor Preclinical Vion
Beta-L-Fd4C3 nucleoside analog RT inhibitor Preclinical Vion
BMS-806 entry inhibitor Phase 1 Bristol-Myers Squibb
Calanolide A non-nucleoside RT inhibitor Phase 2 Sarawak Medichem
Capravirine non-nucleoside RT inhibitor Phase 2 Pfizer/Agouron
DAPD nucleoside analog RT inhibitor Phase 1-2 Triangle Pharmaceuticals
DEHSPM inhibits hypusin/eIF-5A Phase 1 SunPharm
DPC 083 non-nucleoside RT inhibitor Phase 1-2 DuPont Pharmaceuticals2
DPC 681 protease inhibitor Preclinical Dupont Pharmaceuticals2
DPC 684 protease inhibitor Preclinical Dupont Pharmaceuticals2
DPC 961 non-nucleoside RT inhibitor Phase 1 DuPont Pharmaceuticals2
Emivirine (MKC-442) non-nucleoside RT inhibitor Phase 3 Triangle Pharmaceuticals
Emtricitabine (FTC) nucleoside analog RT inhibitor Phase 3 Triangle Pharmaceuticals
HI-2363 non-nucleoside RT inhibitor Preclinical Wayne Hughes Institute
Hu5A83 binding inhibitor Preclinical Tanox
Hydroxyurea inhibits cellular factors Phase 2-3 Bristol-Myers Squibb
L-870,810 integrase inhibitor Phase 1 Merck & Co.
LB-713503 protease inhibitor Preclinical LG Chemical
Mycophenlate inhibits cellular factors Phase 1-2 Hoffman-La Roche
Peldesine inhibits cellular factors Phase 1 Biocryst
Pentfuside (T-20) fusion inhibitor Phase 31 Trimeris/Roche
Phosphazid3 nucleoside analog RT inhibitor Preclinical Viscount
PNU142721 non-nucleoside RT inhibitor Preclinical Pharmacia
PRO 140 CCR5 antagonist Preclinical Progenics
PRO 367 entry inhibitor Phase 1 Progenics
PRO 542 attachment inhibitor Phase 1-2 Progenics
RD4-22173 non-nucleoside RT inhibitor Preclinical Tosoh
Resveratrol inhibits cellular factors Phase 1 Pharmascience
S-1360 integrase inhibitor Phase 1-2 Shionogi Pharmaceuticals
SCH C CCR5 antagonist Phase 1 Schering Plough
SCH D CCR5 antagonist Preclinical Schering Plough
SJ-33663 non-nucleoside RT inhibitor Preclinical Samjin
T-1249 fusion inhibitor Phase 1 Trimeris/Roche
TAK 449 CCR5 antagonist Preclinical Takeda
Tipranavir protease inhibitor Phase 1-2 Boehringer Ingelheim
TMC 125 non-nucleoside RT inhibitor Phase 2 Tibotec Virco
TMC 120 non-nucleoside RT inhibitor Phase 2 Tibotec Virco
TMC 126 protease inhibitor Phase 1 Tibotec Virco
UC-7813 non-nucleoside RT inhibitor Preclinical Uniroyal
UK-427,857 CCR5 antagonist Preclinical Pfizer
VX-175/GW433908 (amprenavir prodrug) protease inhibitor Phase 2-3 Vertex/GlaxoSmithKline


Note: RT stands for Reverse Transcriptase

  1. Available in expanded access

  2. Dupont Pharmaceuticals sold its anti-HIV drug Sustiva and its HIV research pipeline to Bristol-Myers Squibb in 2001

    Advertisement

  3. No information available

  4. Ben Cheng is now the Project Manager at the Forum for Collaborative HIV Research in Washington, DC (www.hivforum.org).


Back to the RITA! Summer 2002 contents page.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!




  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
This article was provided by The Center for AIDS. It is a part of the publication Research Initiative/Treatment Action!. Visit CFA's website to find out more about their activities and publications.
 
See Also
More on HIV Medications
More on HIV Drugs in Development

Tools
 

Advertisement